Dupilumab for the treatment of prurigo nodularis

Prurigo nodularis (PN) is a chronic, intensely pruritic dermatosis driven by neural and immune dysregulation, with historically limited FDA-approved treatment options. In September 2022, dupilumab became the first FDA-approved therapy for PN. To review the clinical efficacy of dupilumab in PN, with...

詳細記述

書誌詳細

主要な著者:	Iain Noel Encarnacion, Noelle Desir, Simona A. Alomary, Nicole J. Baker, Nicholas Mollanazar
フォーマット:	Artigo
言語:	Inglês
出版事項:	Taylor & Francis Group 2026-12-01
シリーズ:	Future Rare Diseases
主題:	Prurigo nodularis dupilumab pharmacokinetics type 2 inflammation LIBERTY-PN PRIME clinical trials worst itch numeric rating scale (WI-NRS)
オンライン･アクセス:	https://www.tandfonline.com/doi/10.1080/23995270.2026.2664390
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!